Table of Contents
A groundbreaking subretinal implant developed in France is showing remarkable promise in partially restoring central vision for patients suffering from dry age-related macular degeneration (AMD), a condition previously without effective therapeutic solutions. Published October 21 in the New England Journal of Medicine, the results signal a major breakthrough in the treatment of this debilitating eye disease.
The innovative device, known as Prima, was created through a collaboration between the Vision Institute (Inserm, CNRS, Sorbonne University) and the start-up Pixium Vision. It utilizes a unique approach to bypass damaged cells and stimulate remaining neural pathways, offering a potential lifeline to those losing their sight.
A Decade in the Making
“The idea for this implant was born almost ten years ago,” explained a research director at Inserm and director of the Vision Institute. The initial concept, however, originated with Daniel Palanker at Stanford University. Researchers then successfully partnered with a French company to develop a clinical version, rigorously validating it in their own laboratories.
The Prima implant itself is a remarkably small photovoltaic microchip, measuring just 2 mm on a side and containing 378 electrodes. Surgically placed under the retina, it functions in conjunction with a pair of smart glasses. These glasses, equipped with a camera and infrared projector, capture images and convert them into light signals. These signals then stimulate the neurons that remain connected to the brain, effectively creating a form of artificial vision. “Unlike older implants, this one is completely wireless,” a lead researcher noted. “This eliminates the risks associated with cables and shortens surgical duration.”
Promising Clinical Trial Results
A clinical trial encompassing 17 European centers and 38 patients yielded impressive results. Six months post-implantation, 81% of participants demonstrated an improvement equivalent to gaining approximately ten additional letters on standard ophthalmological charts. After a year, a significant number were able to read words and even short sentences.
However, the restoration of vision isn’t simply a matter of surgery. “It’s a lot of adjustment work between the patient, the orthoptists and the device,” explained a professor of ophthalmology at Bordeaux University Hospital. “The brain must be re-educated, the camera adjusted, and the implant adapted. It takes time and requires strong motivation.”
According to data presented by Sciences and Life on October 21, 27 of the 32 patients who completed the rehabilitation program achieved independent reading, with an average improvement of five levels of visual acuity and a remarkable improvement of up to twelve levels for one individual. “It’s not natural vision, it’s functional vision,” emphasized a surgeon at Moorfields Eye Hospital in London. “It takes time to adapt to it.”
The experience of Sheila Irvine, 75, powerfully illustrates this progress. “Before, I only saw black shadows. Seeing a letter again for the first time was incredible. I had to learn to read again, but it was worth every effort.”
A Cautious Optimism
Researchers are keen to emphasize that the Prima implant doesn’t restore previous vision. “Patients do not regain their previous vision. We cannot hope to recover what was there before AMD,” cautioned a professor of ophthalmology. “It’s progress, but not a miracle.” Fortunately, observed adverse effects, such as retinal detachments and ocular hypertension, were rare and transient, with overall tolerance deemed “generally good” by researchers.
Pixium Vision was recently acquired by the American company Science Corporation, but a firm marketing date for the Prima implant has not yet been announced. Nevertheless, this French technology represents a significant step forward. “Thanks to this implant, it is possible to restore useful central vision in patients who no longer had a therapeutic alternative,” summarized a leading ophthalmologist.
Looking ahead, researchers are exploring adapting this technology to treat other conditions like Stargardt disease and retinopathy pigmentosa. They also aim to enhance the implant’s resolution to provide even finer vision, potentially even in grayscale.
The result of a successful collaboration between French research institutions and Stanford University, this technological achievement marks a turning point for countless patients. It doesn’t restore perfect vision, but it restores vision.
